Uric acid levels in subjects with bipolar disorder: A comparative meta-analysis

Journal of Psychiatric Research

Volumn 81, Issue , 2016, Pages 133-139

  Bartoli, Francesco ^a   Crocamo, Cristina ^a   Mazza, Mario Gennaro ^a   Clerici, Massimo ^a   Carrà, Giuseppe ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine; Bipolar disorder; Mania; Meta analysis; Purinergic system; Uric acid

Indexed keywords

URIC ACID;

BIPOLAR DISORDER; COMPARATIVE STUDY; DISEASE MARKER; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MIXED ANXIETY AND DEPRESSION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL; BIBLIOGRAPHIC DATABASE; METABOLISM; STATISTICS AND NUMERICAL DATA;

BIPOLAR DISORDER; DATABASES, BIBLIOGRAPHIC; HUMANS; URIC ACID;

EID: 84978412229     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2016.07.007     Document Type: Review

References (47)

1. Abbracchio, M.P., Burnstock, G., Verkhratsky, A., Zimmermann, H., Purinergic signalling in the nervous system: an overview. Trends Neurosci. 32 (2009), 19–29.
2. Akhondzadeh, S., Milajerdi, M.R., Amini, H., Tehrani-Doost, M., Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 8 (2006), 485–489.
3. Albert, U., De Cori, D., Aguglia, A., Barbaro, F., Bogetto, F., Maina, G., Increased uric acid levels in bipolar disorder subjects during different phases of illness. J. Affect. Disord. 173 (2015), 170–175.
4. Ames, B.N., Cathcart, R., Schwiers, E., Hochstein, P., Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 6858–6862.
5. Bartoli, F., Carrà, G., Crocamo, C., Carretta, D., Clerici, M., Bipolar disorder, schizophrenia, and metabolic syndrome. Am. J. Psychiatry 170 (2013), 927–928.
6. Bartoli, F., Crocamo, C., Gennaro, G.M., Castagna, G., Trotta, G., Clerici, M., Carrà, G., Exploring the association between bipolar disorder and uric acid: a mediation analysis. J. Psychosom. Res. 84 (2016), 56–59.
7. Bortolasci, C.C., Vargas, H.O., Vargas Nunes, S.O., de Melo, L.G., de Castro, M.R., Moreira, E.G., Dodd, S., Barbosa, D.S., Berk, M., Maes, M., Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. J. Affect. Disord. 179 (2015), 148–155.
8. Burnstock, G., Pathophysiology and therapeutic potential of purinergic signalling. Pharmacol. Rev. 58 (2006), 58–86.
9. Burnstock, G., Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 87 (2007), 659–797.
10. Burnstock, G., Purinergic signalling and disorders of the central nervous system. Nat. Rev. Drug Discov. 7 (2008), 575–590.
11. Carrà, G., Bartoli, F., Carretta, D., Crocamo, C., Bozzetti, A., Clerici, M., Bebbington, P.E., The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis. Soc. Psychiatry. Psychiatr. Epidemiol. 49 (2014), 1739–1746.
12. Chiu, C.C., Chen, C.H., Huang, M.C., Chen, P.Y., Tsai, C.J., Lu, M.L., The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol. 32 (2012), 585–592.
13. Cohen, J., Statistical Power Analysis for the Behavioral Sciences. second ed., 1988, Lawrence Erlbaum Associates, New York.
14. De Berardis, D., Conti, C.M., Campanella, D., Carano, A., Di Giuseppe, B., Valchera, A., Tancredi, L., Serroni, N., Pizzorno, A.M., Fulcheri, M., Gambi, F., Sepede, G., Moschetta, F.S., Salerno, R.M., Ferro, F.M., Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J. Biol. Regul. Homeost. Agents 22 (2008), 195–200.
15. de Oliveira, E.P., Burini, R.C., High plasma uric acid concentration: causes and consequences. Diabetol. Metab. Syndr., 4, 2012, 12.
16. Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
17. Ezzaher, A., Haj, M.D., Mechri, A., Neffati, F., Douki, W., Gaha, L., TBARs and non-enzymatic antioxidant parameters in Tunisian bipolar I patients. Immuno Anal. Biol. Spec. 27 (2012), 315–324.
18. Fagiolini, A., Chengappa, K.N., Soreca, I., Chang, J., Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS drugs 22 (2008), 655–669.
19. Godin, O., Leboyer, M., Gaman, A., Aouizerate, B., Berna, F., Brunel, L., Capdevielle, D., Chereau, I., Dorey, J.M., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Le Strat, Y., Llorca, P.M., Misdrahi, D., Rey, R., Richieri, R., Passerieux, C., Schandrin, A., Schurhoff, F., Urbach, M., Vidalhet, P., Girerd, N., Fond, G., group, F.-S., Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort. Schizophr. Res. 168 (2015), 388–394.
20. Grassi, D., Ferri, L., Desideri, G., Di Giosia, P., Cheli, P., Del Pinto, R., Properzi, G., Ferri, C., Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr. Pharm. Des. 19 (2013), 2432–2438.
21. Gultekin, B.K., Kesebir, S., Kabak, S.G., Ergun, F.F., Tatlidil Yaylaci, E., Are uric acid levels different from healthy subjects in bipolar affective disorder and schizophrenia?: relationship between clinical improvement and episode severity in male patients. Noropsikiyatri Ars. 51 (2014), 229–232.
22. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
23. Hirota, T., Kishi, T., Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr. Res. 149 (2013), 88–95.
24. Jahangard, L., Soroush, S., Haghighi, M., Ghaleiha, A., Bajoghli, H., Holsboer-Trachsler, E., Brand, S., In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur. Neuropsychopharmacol. 24 (2014), 1210–1221.
25. Kesebir, S., Suner, O., Yaylaci, E.T., Bayrak, A., Turan, C., Increased uric acid levels in bipolar disorder: is it trait or state?. J. Biol. Regul. Homeost. Agents 27 (2013), 981–988.
26. Kesebir, S., Tatlıdil Yaylacı, E., Süner, O., Gültekin, B.K., Uric acid levels may be a biological marker for the differentiation of unipolar and bipolar disorder: the role of affective temperament. J. Affect. Disord. 165 (2014), 131–134.
27. Keshavarz, M., Khosravizadegan, F., Bibak, A., Serum uric acid levels in different phases of acute severe manic and depressed patients. Arch. Neurosci., 2016, 10.5812/archneurosci.30236.
28. Kim, S.Y., Guevara, J.P., Kim, K.M., Choi, H.K., Heitjan, D.F., Albert, D.A., Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 62 (2010), 170–180.
29. Kim, Y.I., Kim, S.M., Hong, J.S., Song, J., Han, D.H., Min, K.J., Lee, Y.S., The correlation between clinical symptoms, serum uric acid level and EEG in patient with bipolar I disorder. J. Korean Neuropsychiatr. Assoc. 55 (2016), 25–32.
30. Krugel, U., Purinergic receptors in psychiatric disorders. Neuropharmacology 104 (2015), 212–225.
31. Lindberg, D., Shan, D., Ayers-Ringler, J., Oliveros, A., Benitez, J., Prieto, M., McCullumsmith, R., Choi, D.S., Purinergic signaling and energy homeostasis in psychiatric disorders. Curr. Mol. Med. 15 (2015), 275–295.
32. Lorenzi, T.M., Borba, D.L., Dutra, G., Lara, D.R., Association of serum uric acid levels with emotional and affective temperaments. J. Affect. Disord. 121 (2010), 161–164.
33. Machado-Vieira, R., Purinergic system in the treatment of bipolar disorder: uric acid levels as a screening test in mania. J. Clin. Psychopharmacol. 32 (2012), 735–736.
34. Machado-Vieira, R., Lara, D.R., Souza, D.O., Kapczinski, F., Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J. Clin. Psychopharmacol. 21 (2001), 621–622.
35. Machado-Vieira, R., Lara, D.R., Souza, D.O., Kapczinski, F., Purinergic dysfunction in mania: an integrative model. Med. Hypotheses 58 (2002), 297–304.
36. Machado-Vieira, R., Soares, J.C., Lara, D.R., Luckenbaugh, D.A., Busnello, J.V., Marca, G., Cunha, A., Souza, D.O., Zarate, C.A. Jr., Kapczinski, F., A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J. Clin. Psychiatry 69 (2008), 1237–1245.
37. Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., Mollace, V., Regulation of uric acid metabolism and excretion. Int. J. Cardiol. 213 (2016), 8–14.
38. McIntyre, R.S., Danilewitz, M., Liauw, S.S., Kemp, D.E., Nguyen, H.T., Kahn, L.S., Kucyi, A., Soczynska, J.K., Woldeyohannes, H.O., Lachowski, A., Kim, B., Nathanson, J., Alsuwaidan, M., Taylor, V.H., Bipolar disorder and metabolic syndrome: an international perspective. J. Affect. Disord. 126 (2010), 366–387.
39. Muti, M., Del Grande, C., Musetti, L., Marazziti, D., Turri, M., Cirronis, M., Pergentini, I., Corsi, M., Dell'Osso, L., Corsini, G.U., Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium. Psychiatry Res. 225 (2015), 604–608.
40. Ortiz, R., Ulrich, H., Zarate, C.A. Jr., Machado-Vieira, R., Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog. Neuropsychopharmacol. Biol. Psychiatry 57 (2015), 117–131.
41. Patsopoulos, N.A., Evangelou, E., Ioannidis, J.P., Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int. J. Epidemiol. 37 (2008), 1148–1157.
42. Salvadore, G., Viale, C.I., Luckenbaugh, D.A., Zanatto, V.C., Portela, L.V., Souza, D.O., Zarate, C.A. Jr., Machado-Vieira, R., Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode. Prog. Neuropsychopharmacol. Biol. Psychiatry 34 (2010), 819–821.
43. Sterne, J.A., Egger, M., Moher, D., Addressing reporting biases. Higgins, J.P., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series, 2008, John Wiley & Sons, Ltd, Chichester, UK, 10.1002/9780470712184.ch10.
44. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher, D., Becker, B.J., Sipe, T.A., Thacker, S.B., Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
45. Wen, S., Cheng, M., Wang, H., Yue, J., Wang, H., Li, G., Zheng, L., Zhong, Z., Peng, F., Serum uric acid levels and the clinical characteristics of depression. Clin. Biochem. 45 (2012), 49–53.
46. Wiener, C., Rassier, G.T., Kaster, M.P., Jansen, K., Pinheiro, R.T., Klamt, F., Magalhães, P.V., Kapczinski, F., Ghisleni, G., da Silva, R.A., Gender-based differences in oxidative stress parameters do not underlie the differences in mood disorders susceptibility between sexes. Eur. Psychiatry 29 (2014), 58–63.
47. Zarate, C.A. Jr., Manji, H.K., Bipolar disorder: candidate drug targets. Mt. Sinai J. Med. 75 (2008), 226–247.